Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28‐week clinical and biomarker results from the BioDay registry

BACKGROUND: Dupilumab has proven to be an effective and safe treatment for atopic dermatitis (AD) in pediatric patients in clinical trials. However, few daily practice studies are available. The aim of this study is to evaluate the effect of 28 weeks dupilumab treatment on effectiveness, safety, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamphuis, Esmé, Boesjes, Celeste M., Loman, Laura, Bakker, Daphne S., Poelhekken, Mila, Zuithoff, Nicolaas P. A., Kamsteeg, Marijke, Romeijn, Geertruida L. E., van Wijk, Femke, de Bruin‐Weller, Marjolein S., de Graaf, Marlies, Schuttelaar, Marie L. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107870/
https://www.ncbi.nlm.nih.gov/pubmed/36564878
http://dx.doi.org/10.1111/pai.13887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107870/
https://www.ncbi.nlm.nih.gov/pubmed/36564878
http://dx.doi.org/10.1111/pai.13887

Ejemplares similares